Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Price Target at $11.13

Sutro Biopharma, Inc. (NASDAQ:STRO) has received a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $11.13.

Several equities analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Sutro Biopharma in a research report on Monday, November 18th. Piper Sandler reiterated an “overweight” rating and set a $11.00 price objective on shares of Sutro Biopharma in a report on Friday, October 11th. Wedbush reissued an “outperform” rating and issued a $8.00 target price on shares of Sutro Biopharma in a research report on Tuesday, December 10th. Wells Fargo & Company dropped their price target on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a report on Wednesday, December 11th.

Institutional Investors Weigh In On Sutro Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Gladius Capital Management LP acquired a new position in Sutro Biopharma in the third quarter worth $28,000. ProShare Advisors LLC lifted its position in shares of Sutro Biopharma by 49.1% in the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock worth $48,000 after buying an additional 5,373 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Sutro Biopharma in the 3rd quarter valued at about $77,000. Intech Investment Management LLC bought a new stake in shares of Sutro Biopharma during the 3rd quarter valued at about $91,000. Finally, The Manufacturers Life Insurance Company raised its stake in Sutro Biopharma by 27.4% during the second quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after acquiring an additional 7,082 shares during the period. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma Stock Performance

Shares of STRO opened at $1.89 on Monday. Sutro Biopharma has a fifty-two week low of $1.70 and a fifty-two week high of $6.13. The company has a market capitalization of $155.85 million, a PE ratio of -1.17 and a beta of 1.09. The stock has a fifty day moving average of $2.91 and a two-hundred day moving average of $3.47.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.